Table of Content

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Bispecific Antibodies Market, by Indication
1.4.2 LAMEA Bispecific Antibodies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Trials and Approvals
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
Chapter 4. LAMEA Bispecific Antibodies Market by Indication
4.1 LAMEA Cancer Market by Country
4.2 LAMEA Inflammatory & Autoimmune Disorder Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Bispecific Antibodies Market by Country
5.1 Brazil Bispecific Antibodies Market
5.1.1 Brazil Bispecific Antibodies Market by Indication
5.2 Argentina Bispecific Antibodies Market
5.2.1 Argentina Bispecific Antibodies Market by Indication
5.3 UAE Bispecific Antibodies Market
5.3.1 UAE Bispecific Antibodies Market by Indication
5.4 Saudi Arabia Bispecific Antibodies Market
5.4.1 Saudi Arabia Bispecific Antibodies Market by Indication
5.5 South Africa Bispecific Antibodies Market
5.5.1 South Africa Bispecific Antibodies Market by Indication
5.6 Nigeria Bispecific Antibodies Market
5.6.1 Nigeria Bispecific Antibodies Market by Indication
5.7 Rest of LAMEA Bispecific Antibodies Market
5.7.1 Rest of LAMEA Bispecific Antibodies Market by Indication
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Trials and Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 Akeso, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Johnson & Johnson (Janssen Global Services, LLC)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental &Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Acquisition and Mergers:
6.6 Taisho Pharmaceuticals Holding Co., Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Immunocore Holdings plc
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 Recent strategies and developments:
6.7.4.1 Partnerships, Collaborations, and Agreements:
6.8 GlaxoSmithKline PLC (GSK)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.9 Novartis AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Allergan PLC (AbbVie, Inc.)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense



List of Figures

FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
FIG 5 LAMEA Bispecific Antibodies Market share by Indication, 2022
FIG 6 LAMEA Bispecific Antibodies Market share by Indication, 2030
FIG 7 LAMEA Bispecific Antibodies Market by Indication, 2019 - 2030, USD Million
FIG 8 LAMEA Bispecific Antibodies Market share by Country, 2022
FIG 9 LAMEA Bispecific Antibodies Market share by Country, 2030
FIG 10 LAMEA Bispecific Antibodies Market by Country, 2019 - 2030, USD Million
FIG 11 Recent strategies and developments: Johnson & Johnson

List of Tables

TABLE 1 LAMEA Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bispecific Antibodies Market
TABLE 4 Trials and Approvals – Bispecific Antibodies Market
TABLE 5 Acquisition and Mergers– Bispecific Antibodies Market
TABLE 6 LAMEA Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 7 LAMEA Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 8 LAMEA Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 LAMEA Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 LAMEA Inflammatory & Autoimmune Disorder Market by Country, 2019 - 2022, USD Million
TABLE 11 LAMEA Inflammatory & Autoimmune Disorder Market by Country, 2023 - 2030, USD Million
TABLE 12 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 13 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 14 LAMEA Bispecific Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 15 LAMEA Bispecific Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 16 Brazil Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 17 Brazil Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 18 Brazil Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 19 Brazil Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 20 Argentina Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 21 Argentina Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 22 Argentina Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 23 Argentina Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 24 UAE Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 25 UAE Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 26 UAE Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 27 UAE Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 28 Saudi Arabia Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 29 Saudi Arabia Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 30 Saudi Arabia Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 31 Saudi Arabia Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 32 South Africa Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 33 South Africa Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 34 South Africa Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 35 South Africa Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 36 Nigeria Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 37 Nigeria Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 38 Nigeria Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 39 Nigeria Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 40 Rest of LAMEA Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 41 Rest of LAMEA Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 42 Rest of LAMEA Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 43 Rest of LAMEA Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 44 Key Information – Amgen, Inc.
TABLE 45 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 46 Key Information – Pfizer, Inc.
TABLE 47 Key Information – Akeso, Inc.
TABLE 48 Key information –Johnson & Johnson
TABLE 49 key Information – Taisho Pharmaceuticals Holding Co., Ltd.
TABLE 50 Key Information – Immunocore Holdings plc
TABLE 51 Key Information – GlaxoSmithKline PLC
TABLE 52 Key Information – Novartis AG
TABLE 53 Key Information – Allergan PLC